Gilead Sciences (GILD) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 0.37.
- Gilead Sciences' Equity Ratio rose 910.86% to 0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37, marking a year-over-year increase of 910.86%. This contributed to the annual value of 0.33 for FY2024, which is 1052.11% down from last year.
- Latest data reveals that Gilead Sciences reported Equity Ratio of 0.37 as of Q3 2025, which was up 910.86% from 0.35 recorded in Q2 2025.
- In the past 5 years, Gilead Sciences' Equity Ratio ranged from a high of 0.37 in Q3 2025 and a low of 0.28 during Q1 2021
- In the last 5 years, Gilead Sciences' Equity Ratio had a median value of 0.34 in 2022 and averaged 0.33.
- Over the last 5 years, Gilead Sciences' Equity Ratio had its largest YoY gain of 1637.69% in 2021, and its largest YoY loss of 2431.53% in 2021.
- Gilead Sciences' Equity Ratio (Quarter) stood at 0.31 in 2021, then increased by 8.31% to 0.34 in 2022, then rose by 9.07% to 0.37 in 2023, then dropped by 10.52% to 0.33 in 2024, then increased by 12.31% to 0.37 in 2025.
- Its Equity Ratio stands at 0.37 for Q3 2025, versus 0.35 for Q2 2025 and 0.34 for Q1 2025.